References
- Elahian F, Sepehrizadeh Z, Moghimi B, Mirzaei SA. Human cytochrome b5 reductase: Structure, function, and potential applications. Crit Rev Biotechnol. 2014;34(2):134–143
- Nagel RL, Jaffé ER. CO-, NO-, met-, and sulf-hemoglobinemias: The dyshemoglobins. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, Eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. New York, NY: Cambridge University Press. 2001:1214–1233
- Giardine B, Borg J, Viennas E, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res. 2014;42 ( Database Issue):D1063–D1069. (http://globin.cse.psu.edu.)
- Do Nascimento TS, Pereira ROL, de Mello HLD, Costa J. Methemoglobinemia: From diagnosis to treatment. Rev Bras Anestesiol. 2008;58(6):651–664
- Hurford WE, Kratz A. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23-2004. A 50-year-old woman with low oxygen saturation. N Engl J Med. 2004;351(4):380–387
- Champigneulle B, Lecorre M, Bouzguenda H, et al. Late diagnosis of congenital methemoglobinemia in an elderly patient during cardiac surgery. J Cardiothorac Vasc Anesth. 2014;28(3):730–732
- Percy MJ, Lappin TR. Recessive congenital methaemoglobinaemia: Cytochrome b(5) reductase deficiency. Br J Haematol. 2008;141(3):298–308
- Warang PP, Kedar PS, Shanmukaiah C, et al. Clinical spectrum and molecular basis of recessive congenital methemoglobinemia in India. Clin Genet. 2015;87(1):62–67
- Molthrop DC, Wheeler RH, Hall KM, Prchal JT. Evaluation of the methemoglobinemia associated with sulofenur. Invest New Drugs. 1994;12(2):99–102